Berman Center for Outcomes & Clinical Research
Better Care through Better Research
Since its inception in 1965, the Berman Center for Outcomes & Clinical Research has been a leader in cardiovascular research and a clinical site for over 100 trials areas such as
- heart and kidney disease
- women’s health
- neurological disorders
For several of these trials, the Berman Center initiated the investigation and was responsible for study design, implementation, and analysis. The Berman Center for Outcomes & Clinical Research is a division of Hennepin Healthcare Research Institute (HHRI), formerly known as Minneapolis Medical Research Foundation (MMRF), which is a subsidiary of Hennepin Healthcare System, Inc.
Hennepin Healthcare is an integrated system of care that includes HCMC, a nationally recognized Level 1 Trauma Center, medical research and teaching hospital located in downtown Minneapolis.
The Berman Center is compliant with Good Clinical Practice (GCP) and/or regulatory requirements consistent with “best practices” guidelines and focuses on outcomes to impact health policy and practice.
As was the intent of founder Dr. Reuben Berman, a pioneer in the field of cardiovascular clinical research, our primary mission is to empower the medical community to offer better patient care through better research.
Chronic Kidney Disease
Northstar: Addiction Medicine Clinical Research
The Northstar Node is member of the National Drug Abuse Treatment Clinical Trials Network (CTN), a means by which medical and specialty treatment providers, treatment researchers, participating patients, and the National Institute on Drug Abuse cooperatively develop, validate, refine, and deliver new treatment options to patients. The Northstar Node is a group of healthcare providers in and around Minneapolis, MN.
Principal Investigators for multi-site trials for which the Berman Center has served either as a regional coordinator or as a clinical site:
Colin B, Baignet, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection
Merit Cudkowicz, MD * Massachusetts General Hospital/Harvard Medical School, Boston, MA * Celebrex in ALS
Robert Byington, PhD * Wake Forest School of Medicine, Winston-Salem, NC * ACCORD, Action to Control Cardiovascular Risks in Diabetes
John McNeil, PhD, MSc * Monash University, Melbourne, Australia * ASPREE, ASPirin in Reducing Events in the Elderly
Charles H. Hennekens, MD, DrPh * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)
Gervasio A. Lamas, MD * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)
Oscar Benavente, MD * University of Texas Health Science Center, San Antonio, TX *
SPS3, Secondary Prevention of Small Subcortical Strokes
Martin Landray, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection
Jeffery Probstfield, MD * University of Washington School of Medicine * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Principal Investigator for U.S. Regional Coordinating Center)
Eric Sorenson, MD * Mayo Clinic, Rochester, MN * IGF-I (Myotrophin) in ALS
Hertzel Gerstein, MD * Professor of Medicine and Chief of Division of Endocrinology
McMaster University Faculty of Health Sciences
Hamilton, Ontario, Canada * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator) * DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (Co-principal Investigator)
Salim Yusuf, MD * Professor of Medicine and Chief of Division of Cardiology
McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator) * ONTARGET/TRANSCEND
OnTarget: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial: A large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events Transcend: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease